Table 3.
Prevalence of moderate-to-severe steatosis, biopsy-proven NASH, and aggregate fibrosis stages in individuals with NAFLD
| Overall results and by diagnostic method | Studies, n | Participants, n | Prevalence (95% CI), % | I2, % | P value |
|---|---|---|---|---|---|
| Moderate-to-severe steatosis | |||||
| Total | 31 | 138,903 | 26.50 (20.79–33.12) | 99.8 | |
| Ultrasound28, 34, 37, 57, 58, 74, 83, 84, 88, 109, 110, 112, 120, 130, 144, 145, 146, 147, 160, 165, 174, 175 | 22 | 136,442 | 25.20 (19.28–32.22) | 99.8 | 0.53 |
| Biopsy3, 53, 82, 95, 104, 111, 132, 137, 138 | 9 | 2,461 | 30.21 (17.65–46.66) | 97.4 | |
| Biopsy-proven NASH79, 95, 96, 104, 137, 138, 188 | 7 | 1,168 | 52.27 (38.13–66.07) | 94.6 | |
| Fibrosis by TE and biopsy | |||||
| <F2 | |||||
| Total | 14 | 5,275 | 85.41 (74.91−91.98) | 98.2 | |
| Liver biopsy51, 53, 95, 96, 104, 111, 137, 138, 188 | 9 | 2,411 | 85.22 (68.58–93.84) | 98.4 | 0.92 |
| TE10, 11, 41, 69, 105 | 5 | 2,864 | 86.00 (74.05–92.97) | 96.9 | |
| ≥F2 | |||||
| Total | 14 | 5,275 | 14.96 (8.17−25.82) | 98.3 | |
| Liver biopsy51, 53, 95, 96, 104, 111, 137, 138, 188 | 9 | 2,411 | 15.37 (6.34–32.75) | 98.5 | 0.86 |
| TE10, 11, 41, 69, 105 | 5 | 2,864 | 14.00 (7.03–25.95) | 96.9 | |
| <F3 | |||||
| Total | 14 | 44,484 | 91.83 (80.79−96.78) | 99.9 | |
| Liver biopsy51, 53, 95, 104, 111, 137, 138, 188 | 8 | 1,995 | 96.85 (85.55–99.38) | 98.0 | 0.02 |
| TE2, 14, 36, 97, 160, 161 | 6 | 42,489 | 79.14 (65.49–88.35) | 99.9 | |
| ≥F3 | |||||
| Total | 14 | 44,484 | 6.50 (2.38−16.58) | 99.9 | |
| Liver biopsy51, 53,95,104,111,137,138,188 | 8 | 1,995 | 3.44 (0.64–16.40) | 98.3 | 0.20 |
| TE2, 14, 36, 97, 160, 161 | 6 | 42,489 | 12.38 (4.06–32.05) | 99.9 | |
Bold values emphasize total values of steatosis, biopsy-proven NASH, and fibrosis stages. NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; TE, transient elastography.